Liothyronine Sodium Morningside Healthcare (Liothyronine Sodium)

Liothyronine is a synthetic form of triiodothyronine (T3). After oral absorption, it enters cells and binds to nuclear thyroid hormone receptors, influencing gene transcription that regulates basal metabolic rate, protein synthesis, and sympathetic activity. This results in increased oxygen consumption, heat production, and overall metabolic acceleration.

The dose of liothyronine sodium is individualized and set by the prescribing clinician based on factors such as the patient’s age, weight, severity of thyroid deficiency, cardiac status, and laboratory thyroid function tests. No standard dosing regimen is provided here; the prescriber adjusts the amount to achieve target hormone levels.

Safety data are limited. Liothyronine should be used in pregnancy only if the potential benefit to the mother outweighs any possible risk to the fetus. During breastfeeding, the drug passes into milk in small amounts; clinicians should assess the infant’s exposure and decide whether continuation is appropriate.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and the necessary import documentation.

The primary alternative is levothyroxine (T4), a pro‑hormone that requires conversion to T3 in peripheral tissues. Liothyronine provides the active hormone directly, leading to a faster onset of action but a shorter half‑life. Levothyroxine offers more stable serum levels and is usually preferred for long‑term maintenance, whereas liothyronine is useful when rapid correction is needed.

Store the product at room temperature, preferably below 25 °C. Keep it in the original packaging, protect it from moisture, excessive heat and direct sunlight. Do not refrigerate or freeze unless the label specifically indicates otherwise.

Liothyronine sodium is taken orally, usually as a tablet or capsule, with or without food as directed by the prescriber. The exact administration schedule (e.g., once daily or divided doses) is determined by the treating clinician based on the individual’s therapeutic needs.

Serious risks include cardiac arrhythmias, angina, myocardial infarction, severe bone loss (osteoporosis) with prolonged use, adrenal insufficiency precipitated by abrupt therapy, and rare but life‑threatening allergic reactions such as anaphylaxis. Patients should be monitored closely for these events, especially if they have underlying heart disease.

Liothyronine is contraindicated in patients with untreated adrenal insufficiency, acute myocardial infarction, or uncontrolled cardiac disease. It should also be avoided in individuals who have demonstrated hypersensitivity to liothyronine or any of the product’s excipients. Clinicians must assess each patient’s medical history before initiating therapy.